|1.||Thompson, Linda F: 9 articles (05/2012 - 10/2002)|
|2.||Eltzschig, Holger K: 9 articles (04/2011 - 10/2002)|
|3.||Battastini, Ana Maria Oliveira: 8 articles (09/2014 - 06/2003)|
|4.||Bonan, Carla Denise: 6 articles (04/2015 - 06/2003)|
|5.||Braganhol, Elizandra: 6 articles (09/2014 - 08/2003)|
|6.||Bruno, Alessandra Nejar: 6 articles (04/2014 - 06/2003)|
|7.||Wink, Márcia R: 6 articles (04/2014 - 02/2007)|
|8.||Zhou, Ping: 6 articles (06/2013 - 01/2007)|
|9.||Zhi, Xiuling: 6 articles (06/2013 - 01/2007)|
|10.||Morsch, Vera Maria: 6 articles (02/2012 - 02/2003)|
11/01/2008 - "Use of soluble 5'-nucleotidase may be a potential therapeutic for hepatic ischemia."
01/01/1992 - "Therefore 5'-nucleotidase inhibitors were administered to isolated, perfused adult rabbit hearts subjected to 120 minutes of ischemia (at 34 degrees C) to determine if this improved functional recovery. "
10/01/1998 - "This study tested the hypothesis that cardiac ecto-5'-nucleotidase (ecto-5'-NT) activity during ischemic preconditioning (PC) contributes to augmented tolerance against ischemia, thereby reducing infarct size in the rabbit heart in situ. "
02/01/1992 - "The purposes of this study were (1) to document 5'-nucleotidase activities in neonatal and adult rabbit myocardium and (2) to correlate differences of 5'-nucleotidase activity with functional recovery from ischemia. "
11/01/2008 - "Reconstitution of cd73(-/-) mice with soluble 5'-nucleotidase resulted in complete restoration of hepatoprotection by IP, and hepatic injury following ischemia was attenuated by treatment of WT mice with soluble 5'-nucleotidase. "
06/01/1981 - "A significant reduction of the activity of 5'-nucleotidase was observed in tumor homogenates compared with homogenates from normal ovaries. "
12/24/2015 - "We used a combined approach based on fragment-based drug design (FBDD) and in silico methods to design potential inhibitors of the cytosolic 5'-nucleotidase II (cN-II), which has been recognized as an important therapeutic target in hematological cancers. "
07/01/2015 - "Determination of the enzymatic activity of cytosolic 5'-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models."
09/01/2014 - "In this work, we investigated the NTPDase3 and ecto-5'-nucleotidase/CD73 expression in cancer progression in vivo. "
09/01/2014 - "The ectonucleotidases, mainly ecto-5'-nucleotidase/CD73 have been revealed as new players in cancer progression and malignity. "
|3.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
05/01/1990 - "5' Nucleotidase in chronic B cell leukemias: a cytochemical and ultrastructural study."
03/01/2002 - "Literature on the behaviour of ecto-5'-nucleotidase in the course of B-cell chronic lymphocytic leukemia is briefly reviewed and aims for further researches are highlighted."
03/01/2002 - "Ecto-5'-nucleotidase in B-cell chronic lymphocytic leukemia."
06/01/1998 - "The activity of membrane-bound ecto-5'-nucleotidase and soluble e-Ns and c-N-II 5'-nucleotidases was evaluated on lymphocytes from patients affected by B-cell chronic lymphocytic leukemia (B-CLL). "
06/01/1998 - "5'-nucleotidase activity in lymphocytes from patients affected by B-cell chronic lymphocytic leukemia."
|4.||Bipolar Disorder (Mania)
05/01/2010 - "In favor of this idea, IMPA2 encoding IMPase is a candidate susceptibility gene for bipolar disorder and that the risk-conferring single nucleotide polymorphisms enhance the promoter activity of IMPA2. "
04/01/2007 - "IMPA2, one of the genes that encode IMPase, is located in a region with linkage to bipolar disorder. "
04/11/2014 - "The enzymatic activity of IMPase is inhibited by lithium, a drug used for the treatment of mood swings seen in bipolar disorder. "
10/01/2012 - "Lithium, which is the drug of choice for bipolar disorder, inhibits IMPase at therapeutically relevant plasma concentrations. "
03/28/2012 - "According to the inositol depletion hypothesis, IMPase activity is assumed to be higher than normal in patients suffering from bipolar disorder. "
09/01/2005 - "The authors review epidemiology, classification, etiology and pathogenesis of erectile dysfunction (ED), its diagnosis and treatment with a focus on mechanisms of action and efficacy of the drug impase. "
11/01/2011 - "The results of the treatment showed that impase addition to combined treatment of CAP patients with erectile dysfunction significantly improves erectile function: 80.6% patients given impase raised their score by International Index of Erectile Function Scale to normal (26 points and higher). "
09/01/2005 - "[Impase in the treatment of erectile dysfunction]."
03/01/2004 - "[Use of impase in the therapy of erectile dysfunction]."
05/01/2003 - "Clinical efficacy and safety of the drug impase in erectile dysfunction (ED) were studied in 30 patients with ED of various genesis (mean age 52.09 +/- 4.75 years). "
|5.||myo-inositol-1 (or 4)-monophosphatase (inositol monophosphatase)
|7.||Alanine Transaminase (SGPT)
|10.||Aspartic Acid (Aspartate)
|1.||Transplantation (Transplant Recipients)
|5.||Homologous Transplantation (Allograft)